Cimzia: Ph III CIMPASI-1 data

Top-line data from the double-blind, international Phase III CIMPASI-1 trial in 234 patients with moderate to severe chronic plaque psoriasis showed that 200 and 400 mg doses of subcutaneous Cimzia every 2 weeks

Read the full 333 word article

User Sign In